BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: Ebola glycoprotein GP1; Marburg glycoprotein GP1; Niemann-Pick disease type C1 (NPC1)

March 19, 2015 7:00 AM UTC

In vitro and mouse studies identified cross-reactive antibodies that could help treat or protect against Ebola and Marburg viral infections. NPC1 is a host factor required for viral entry by both Marb...